The Time is Now: Focusing on New and Emerging Therapies for Improving Patient Outcomes in AML

Release date: August 20, 2018
Expiration date: August 20, 2019

 

FACULTY

Jorge E. Cortes, MD
Jane and John Justin Distinguished Chair in Leukemia Research
Section Chief of AML & CML
Deputy Chairman
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts

PROGRAM OVERVIEW

Despite recent advances in understanding of the pathophysiology of AML and a corresponding expansion of targeted treatment modalities, the care of individuals with the disease remains a significant challenge in current clinical practice. The following program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote accurate disease classification and risk assessment, and personalized treatment for patients with AML, including older individuals and those with relapsing or refractory disease.

TARGET AUDIENCE

This program is intended for hematologists, medical oncologists, health system pharmacists, oncology nurses, NPs, PAs, and other HCPs involved in the care of patients with AML.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe the pathophysiology of AML and identify potential therapeutic targets
  • Summarize current clinical trial evidence regarding the efficacy and safety of new and emerging therapies for AML
  • Outline an approach to AML treatment selection that is tailored based upon individual patient characteristics
 DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 20, 2018 through August 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A certificate will be issued only upon receipt of a completed activity evaluation form and a successful posttest with a score of 70% or higher.

MEDIA

Internet

ACCREDITATION STATMENT

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONCTACT INFORMTIION

For information about this activity, please contact the University of Nebraska Medical Center, Center for Continuing Education at (402) 559-4152 or via email at conted@unmc.edu.

 DISCLOSURE OF CONFLICTS OF INTEREST

The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jorge E. Cortes, MD has no real or apparent conflicts of interest to report.

Richard M. Stone, MD
Consultant: Abbvie, Agios, Amgen, Argenix, Arog, Astellas, Celator, Celgene, Cornerstone, Fujifilm, Janssen, Jazz, Juno, Karyopharm, Merck, Novartis, Ono, Orsenix, Otsuka, Pfizer
Research: Agios, Arog, Novartis
Board Member: Actinium
Steering Committee: Celgene

Patima Tanapat, PhD, has no real or apparent conflicts of interest to report.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Nebraska Medical Center, Center for Continuing Education, Integrity Continuing Education, Inc. and Pfizer do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

This activity is co-provided by University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGMENT

This activity is supported by an educational grant from Pfizer.

Continue to Pretest